Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Fulcrum Therapeutics, Inc. (FULC : NSDQ)

• Company Description    Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $8.30 Daily Weekly Monthly 20 Day Moving Average: 834,872 shares Shares Outstanding: 40.85 (millions) Market Capitalization: $339.04 (millions) Beta: 2.52 52 Week High: $33.10 52 Week Low: $6.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -37.41% -31.41% 12 Week -18.71% -11.79% Year To Date -53.08% -44.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 26 LANDSDOWNE STREET - CAMBRIDGE,MA 02139 USA ph: 617-651-8851 fax: - cwaarich@fulcrumtx.com http://www.fulcrumtx.com

• General Corporate Information    Officers Bryan Stuart - Chief Executive Officer and President Kate Haviland - Chairman Esther Rajavelu - Chief Financial Officer Peter Thomson - Vice President; Finance and Accounting Sonja Banks - Director Peer Information Fulcrum Therapeutics, Inc. (CORR.) Fulcrum Therapeutics, Inc. (RSPI) Fulcrum Therapeutics, Inc. (CGXP) Fulcrum Therapeutics, Inc. (BGEN) Fulcrum Therapeutics, Inc. (GTBP) Fulcrum Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 359616109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 40.85 Most Recent Split Date: (:1) Beta: 2.52 Market Capitalization: $339.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 12.20% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.78 Price/Cash Flow: - Price / Sales: 19.98 EPS Growth vs. Year Ago Period: -18.52% vs. Previous Quarter: -10.34% Sales Growth vs. Year Ago Period: -45.88% vs. Previous Quarter: -48.75% ROE 03/31/22 - -48.38 12/31/21 - -47.50 09/30/21 - -53.21 ROA 03/31/22 - -42.31 12/31/21 - -41.20 09/30/21 - -44.20 Current Ratio 03/31/22 - 10.94 12/31/21 - 11.77 09/30/21 - 11.95 Quick Ratio 03/31/22 - 10.94 12/31/21 - 11.77 09/30/21 - 11.95 Operating Margin 03/31/22 - -529.15 12/31/21 - -421.89 09/30/21 - -409.62 Net Margin 03/31/22 - -529.15 12/31/21 - -421.89 09/30/21 - -409.62 Pre-Tax Margin 03/31/22 - -529.15 12/31/21 - -421.89 09/30/21 - -409.62 Book Value 03/31/22 - 4.63 12/31/21 - 5.22 09/30/21 - 5.69 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©